ACS rolls out new process for developing cancer guidelines


Many organizations develop guidelines for the prevention, diagnosis, and treatment of cancer (prostate cancer included). And the differences between these guidelines can be striking and controversial … depending on who participates in the process of guideline development, who is writing them, how decisions are made, and who has additional input as expert third parties.

The American Cancer Society (ACS) has traditionally developed their guidelines based on a process of evidence review by specialists in cancer management (medical oncologists and other relevant specialists, such as urologists and radiation oncologists in the case of prostate cancer). However, they are about to adopt a radically different model, described in detail a new article in the Journal of the American Medical Association. Additional information is available in a media release from the ACS and in an article on the Reuters web site.

The new process proposed by the ACS is very different. It will eliminate all specialists (who have inevitable, potential conflicts of interest) from voting on or actually writing all final guidelines. These specialists will still be able to offer their views and their input to the process, but they will not be able to actually decide or otherwise determine the content of actual guidelines … because the guidelines will be written by “generalists” — primary care physicians, public health physicans, etc., who have no personal “skin in the game” when it comes to the treatment of patients. Each guidelines committee will also include at least one patient advocate … who will hopefully be someone who is truly committed to objectivity and is not selected because of his or her “political” importance and associations (a common problem with the selection of patient representatives on national committees).

The available information is explicit that the new process is intended to be highly transparent, and is based on a set of processes laid out in a report from the Institute of Medicine, published in March this year.

It is going to be extremely interesting to compare the recommendations of guidelines developed by this new process with the historic guidelines on prostate cancer issued by the ACS as well as those issued by other organizations (the National Institutes of Health, the National Comprehensive Cancer Network, and the American Urological Association being the prime examples in the case of prostate cancer). Quite when the ACS will get around to issuing its first guidelines on prostate cancer using this process has yet to be clarified. However, The “New” Prostate Cancer InfoLink suspects they are going to be very different from anything we are used to seeing from any of the historic guideline-setting organizations. For starters, I don’t think a guideline developed by this process will use the words “gold standard” for any currently available form of treatment of localized prostate cancer!

We can hardly wait to see what comes out of this process! And of course even with such new guidelines in place, the willingness of members of the specialist treatment community to abide by such guidelines could also be open to considerable question.

 

 

 

2 Responses

  1. A hopeful and necessary clinical and market correction.

  2. Very exciting news, Michael. The me-first imperative of professional trade organizations and healthcare entities run as businesses by external investors most interested in ROI with “skin in the game” — this is what perverts our present healthcare system and does a disservice to patients.

    The transparency of the Internet will put an end to all these games. I’m looking forward to the return of medicine as a respected and suitably compensated honorable profession rather than its present meat-market (with patients as unsuspecting commodities, their body parts and “treatments” being marketed, bought and sold like widgets at a bazaar).

    From my perspective, the first thing is to stop the creation of all these new prostate “cancer” patients. The medical industry can make a lot more money off someone if he has that label. (Please, please don’t misinterpret this. I am not saying that the diagnosis of “cancer” is not appropriate when it has a good chance of leading to treatment that benefits the patient.) The term just shouldn’t be used as widely as it currently is to describe a natural aging process that may not have significant potential to harm.

    If taxpayer money is being spent, let it serve the interests of those who pay the taxes or society at large .

    If private money is spent, a transparent marketplace will enable an informed consumer to make reasonable decisions using their own values.

    DrO

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: